SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the FDAs upcoming decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders citing the amended upper-limb data, rare-disease policy discussions and recent launch-related hiring as reasons for optimism. Others caution that approval is uncertain given the prior negative review and continuing questions about the evidence.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS commercial uptake are driving attention, with traders highlighting the companys return to profitability and potential for further growth. The upbeat reaction is accompanied by short-squeeze speculation and interest in upcoming PRGN-2009 data and European expansion.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A run to a 52-week high has traders positioning around the expected Q3 earnings report, with BRIUMVIs sales growth supporting optimism. Buyout rumors and heavy short interest are fueling squeeze speculation, though some traders see earnings expectationsnot a confirmed acquisitionas the main driver.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths post-TDAPA Medicare add-on could fall sharply after Q1 2027 has fueled concerns about pricing and CorMedix revenue amid a steep selloff. Traders dispute whether DaVitas preliminary outlook signals a broader reimbursement decline, pointing to CMSs published estimate, while others criticize management for not clarifying the potential impact.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL leukemia trial reached its prespecified 80th death event, triggering final analysis and putting the GPS survival readout at the center of discussion. Traders are divided between optimism about a strong result and concerns about the control arm and trial design, while shares have come under pressure ahead of the binary catalyst.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp technology and AI-linked selloffintensified by Intels weak outlook and concerns about returns on heavy AI investmentis driving attention to QQQ. Traders are split between warning of more downside and treating the drop as an oversold dip with potential for a rebound.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure amid a semiconductor and tech selloff, as traders question whether heavy AI infrastructure spending will generate adequate returns; weak Intel guidance and concerns about Amazons elevated capex are cited as contributing pressures. The community is divided between expecting a deeper unwind in the AI trade and seeing oversold conditions and technical support as possible grounds for a bounce.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas strong quarterly results and raised outlook, alongside expectations that AI agents will increase demand for identity security, fueled a sharp rally. Traders are now debating whether the growth outlook justifies the valuation, with some taking profits or positioning for a pullback.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by growth in Eylea HD and Sanofi collaboration revenue from Dupixent, drove a sharp share-price gain. Traders largely celebrated the earnings beat and breakout, while some pointed to the upcoming cemdisiran decision as another potential catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are SGRY, RRC, PAG Obtaining Fair Deals for their Shareholders?

Are SGRY, RRC, PAG Obtaining Fair Deals for their Shareholders? Are SGRY, RRC, PAG Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 30, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...

XOM Q3 Earnings & Revenues Beat Estimates on Strong Refining Margins

ExxonMobil surpasses Q3 estimates as record refining margins lift earnings, cash flow and shareholder returns despite Middle East disruptions.

EQT CEO Toby Rice on buying Range Resources: We've created a higher-quality business

EQT CEO Toby Rice on buying Range Resources: We've created a higher-quality business...

BKR Q3 Earnings Beat Estimates on Strong IET Growth & Chart Gains

Baker Hughes surpasses Q3 earnings estimates as Chart boosts revenues, orders up 31% and strong IET demand drives higher 2026 outlook.

EQT and Range Resources Are Merging: Is It Time to Buy the New U.S. Natural Gas Titan?

Key PointsRange will give EQT more liquids-rich natural gas...

EQT Q3 Earnings Beat Estimates on Lower Operating Costs, Revenues Miss

EQT surpasses Q3 earnings estimates despite lower gas volumes, revenues and cash flow, while its Range Resources merger promises scale and cost savings.

EQT to Acquire Range Resources, Create a Leading Natural Gas Company

EQT's all-stock deal for Range Resources creates a natural gas producer worth $50B-plus, targeting major cost savings and stronger free cash flow.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Range Resources Corporation (NYSE: RRC)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Range Resources Corporation (NYSE: RRC) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Range Resources Corporation (NYSE: RRC)PR NewswireNEW YORK, Oct. 28, 2026 NEW YORK, Oct. 28, 2026...

Range Resources Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Range Resources Corporation - RRC

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Range Resources Corporation (NYSE: RRC) to EQT Corporation (NYSE: EQT). Under the terms of the proposed transaction, shareholders of Range will...

Range Resources (RRC) Surpasses Q3 Earnings and Revenue Estimates

Range Resources (RRC) delivered earnings and revenue surprises of +15.71% and +4.82%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

• Reported GAAP EPS of $0.75 up 31.58% YoY
• Reported revenue of $784.44M up 19.71% YoY

Range Resources faced higher Q3 unit operating and transportation costs, lower natural-gas benchmarks amid production growth and uncertain winter demand, and merger approval, completion and potential termination-fee risks.

Range Resources recorded higher Q3 sales alongside 12% production growth, generated increased operating cash flow, maintained $1.5B of facility liquidity, and paid a higher $0.10 per-share dividend.

Range Resources Corp. engages in the exploration, development, and acquisition of natural gas and oil properties in the Appalachian and Midcontinent regions. The company was founded in 1976 and is headquartered in Fort Worth, TX.

Range Resources Corp

EQT’s Range Resources Buyout Draws Questions From Scotiabank — Firm Asks Why Pay For RRC’s Assets In Current Commodity Price Environment 

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>Scotiabank lowered EQT’s price target to $53 from $54 and maintained a ‘Sector Perform’ rating, according to The Fly.</li><li>UBS expects the acquisition to be positive despite near-term dilution for EQT.</li><li>Wells Fargo said near-term weakness in the U.S. gas market presents an attractive buying opportunity in EQT shares.</li></ul><p>EQT Corp.’s (EQT) proposed acquisition of Range Resources (RRC) has drawn mixed reactions from Wall Street, with Scotiabank questioning why the deal is being considered amid weak U.S. natural gas prices and uncertainty about demand.</p><p>The firm lowered EQT’s price target to $53 from $54 and maintained a ‘Sector Perform’ rating, according to The Fly. This represents a 4.5% downside from current levels.</p><p><a href="https://stocktwits.com/symbol/EQT">EQT shares</a> were up 0.6% at the time of writing, having closed in the red on Monday.</p><h2 class="st-heading-2">Scotiabank Sees Risk In Power Demand</h2><p>Scotiabank questioned why EQT is willing to pay for Range Resources’ assets at current commodity prices, given that much of the deal’s value depends on higher long-term natural regional gas demand.</p><p>The firm also said that it sees risks to the magnitude and timing of power demand from data centers.</p><p>U.S. natural gas prices have come under pressure lately from rising production and forecasts of warmer weather. The ProShares Ultra Bloomberg Natural Gas ETF (BOIL) fell 3.3% on Tuesday and is tracking its fifth straight monthly loss.&nbsp;</p><p>Natural gas futures for December 2026 deliveries were down about 1% at about $3 per million British thermal units (MMBtu) at the time of writing.</p><h2 class="st-heading-2">EQT To Own 73% Of Combined Firm</h2><p>On Monday, EQT <a href="https://stocktwits.com/news-articles/markets/equity/rrc-stock-surges-to-over-11-year-high-rbrk-shares-hit-record-levels/cZU3JjBRBzc">announced</a> a deal to acquire Range Resources in an all-stock transaction, creating “America’s largest and only vertically integrated natural gas producer,” with a combined enterprise value exceeding $50 billion.</p><p>Existing EQT shareholders will own about 73% of the combined company, while Range Resources investors will hold the remaining 27%. EQT expects the merger to generate $325 million in annual savings within two years, potentially exceeding $600 million over the longer term. The company also projects about $20 billion in cumulative free cash flow over five years.</p><h2 class="st-heading-2">UBS Sees Long-Term Value In RRC Acquisition</h2><p>UBS also lowered its price target on EQT to $75 from $76 and maintained a ‘Buy’ rating. The brokerage expects the acquisition to be positive despite near-term dilution. The firm expects the Range Resources acquisition to be 4% to 7% dilutive to full-year 2027 and 2028 earnings estimates, according to Investing.com.</p><p>However, UBS sees long-term value for EQT, including higher inventory quality and depth, reduced costs, and improved financial strength.</p><h2 class="st-heading-2">Wells Fargo Sees Buying Opportunity</h2><p>Wells Fargo lowered EQT’s price target to $71 from $79 but maintained an ‘Overweight’ rating. The brokerage cited the price cut to near-term weakness in the U.S. gas market, including forecasts of an El Niño winter, which could raise temperatures and lower heating demand.</p><p>However, Wells Fargo believes near-term weakness in the gas market presents an attractive buying opportunity ahead of the merger’s expected completion in the first quarter of 2027.</p><h2 class="st-heading-2">Retail’s Take On EQT And RRC</h2><p>Retail sentiment surrounding EQT on Stocktwits turned ‘bullish’ from ‘neutral’ over the past 24 hours, amid ‘high’ message volumes. Sentiment for&nbsp; RRC turned ‘neutral’ from ‘bullish.’</p><p><img src="https://news.stocktwits-cdn.com/EQT_20600e06b9.png" alt="EQT.png"></p><p>EQT shares have climbed about 3.6% so far in 2026, significantly underperforming RRC’s 54% gains.</p><p><strong>Also read: </strong><a href="https://stocktwits.com/news-articles/markets/equity/light-path-secures-massive-drone-optics-order-ceo-calls-deal-a-significant-milestone-for-defense-business/cZUefOYRBC1"><strong>LightPath Secures Massive Drone Optics Order — CEO Calls Deal A ‘Significant Milestone’ For Defense Business</strong></a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the EQT Corporation company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Scotiabank said it sees risks to the magnitude and timing of power demand from data centers.

EQT’s Range Resources Buyout Draws Questions From Scotiabank — Firm Asks Why Pay For RRC’s Assets In Current Commodity Price Environment

ProShares Ultra Bloomberg Natural Gas

EQT Corp

ProShares UltraShort Bloomberg Natural Gas

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$1.05	--	--	N/A
Q3 '26	$0.75	$0.81	8.05%	BEAT
Q2 '26	$0.65	$0.79	20.75%	BEAT
Q1 '26	$1.30	$1.52	16.57%	BEAT
Q4 '25	$0.71	$0.82	15.01%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

RRC Earnings

Latest Earnings Results: Q3 '26

Historical Earnings